Parkinson's disease
Conditions
Interventions
Probiotics group :Lactobacillus plantarum CCFM405
Placebo group:Probiotic products without CCFM405
Sponsors
Yancheng Tinghu District People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients meeting the following criteria are eligible to participate in the study ? PD was clinically diagnosed by MDS (International Dyspraxia Association) in 2015; ? Constipation in accordance with the Roman ? criteria must include two or more of the following symptoms: at least 25% of the constipation experience difficulty; At least 25% of bowel movements are lumpy or stiff; At least 25% of bowel movements have a lack of bowel movement; Anorectal obstruction in at least 25% of defecation; At least 25% of defecation requires manual assistance (finger picking, pelvic floor support); Defecation less than 3 times a week; ? 18-75 years old, male and female; ? No serious cognitive dysfunction affecting written and spoken expression; ? No serious aphasia or hearing impairment; ? The patient fills out a written informed consent form, basic information questionnaire, dietary structure and living condition questionnaire, and promises to cooperate with the research throughout the entire experimental period.
Exclusion criteria
Exclusion criteria: Patients who met one of the following exclusion criteria were excluded from the study. ? Serious cognitive dysfunction affecting written and spoken expression; ? severe aphasia or dysarthria; ? Suffering from mental illness and unable to carry out relevant examinations as required; ? other serious physical diseases or severe abnormalities of liver and kidney function; ? Patients who have received surgical treatment for PD; ? Patients who need to take immunosuppressants for a long time or take antibiotics within 1 month before enrollment and take antibiotics during follow-up; ? During the follow-up period, patients took defecation promoting drugs, such as polyethylene glycol electrolyte, phenolphthalein tablets, senna leaf, etc.; ? suffering from chronic digestive system diseases or tumors, such as digestive tract ulcers, inflammatory enteritis, serious liver disease patients; ? Patients with irregular eating habits and great changes during the follow-up; ? Patients with chronic digestive diseases or tumors, such as digestive tract ulcers, inflammatory enteritis, and severe liver disease. ? Persons who are allergic to the test sample or have obvious digestive tract symptoms that they cannot tolerate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Motor symptoms and non-motor symptoms;Depression;Anxiety;Sleep;Constipation quality of life;39 item Parkinson’s Disease Questionnaire;Hoehn and Yahr stage;The number of bowel movements;The Bristol Stool Form Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Gut microbiota;Fecal metabolites; | — |
Countries
China
Contacts
Public ContactSongli Zhang; Jianxin Zhao
Tinghu People's Hospital of Yancheng City; Jiangnan University
Outcome results
None listed